Dr. William S. Marshall joins the Business Advisory Board of AmideBio, LLC
BOULDER, CO, August 9, 2012 – AmideBio, LLC, a privately held biopharmaceutical company that develops novel recombinant manufacturing processes for peptides and proteins, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen Therapeutics, Inc., has joined AmideBio’s Business Advisory Board. Dr. Marshall will play a key role in advising the Company on commercial and strategic goals focused on future growth.
Dr. Misha Plam, AmideBio’s President and CEO, commented that “Dr. Marshall’s willingness to provide informal advice to AmideBio has played a significant role in our business and scientific progress from the inception of the Company. We are especially gratified that Bill has now taken a more formal role at AmideBio, enabling him to continue to guide us toward industry-leading solutions to some of the most challenging yet commercially important problems in the large-scale production of high-quality proteins and peptides.”
“The AmideBio technology offers a compelling solution to the significant issues surrounding reliable, cost effective production of complex peptides,” said Dr. Marshall. “Molecules of this class represent attractive drug candidates across a range of therapeutic indications, but their development has been hindered because of pharmacoeconomic considerations. I’m very excited about the potential of the AmideBio approach to open new avenues for the development of life changing medicines.”
Prior to establishing miRagen, Dr. Marshall was Vice President of Technology and Business Development for Bioscience at Thermo Fisher Scientific. In this role, he was responsible for leading technology assessment and strategic planning for the Thermo Fisher Biosciences Division, a business unit that generates approximately $1 billion in revenues from the manufacture and supply of a wide range of products and services across the general-chemistry and life-sciences arenas.
Dr. Marshall was one of the scientific founders of Dharmacon, Inc., which was acquired by Fisher Scientific International, serving as the Executive Vice President for Research and Operations and General Manager. Prior to joining Dharmacon, Dr. Marshall served in many capacities at Amgen, Inc., most recently as Associate Director of Research, Site Head for Research and Head of the Nucleic Acid and Peptide Technology Department. In these positions, he participated in a wide variety of therapeutic development approaches throughout the drug discovery process leading to the development of clinical candidates.
Dr. Marshall received his B.S. in Biochemistry from the University of Wisconsin-Madison and his Ph.D. in Chemistry from the University of Colorado at Boulder in the laboratory of Professor Marvin Caruthers. He is author or co-author of over 50 research papers and 30 patents.
AmideBio, based in Boulder, CO, is an early-stage biotechnology company that has developed a unique technology for producing peptides and proteins, especially ones that previously were difficult to manufacture in large quantities. The Company is expanding its proprietary technology platform in the areas of protein production, biosimilar therapeutic manufacturing, and internal research and development of novel targets for biotherapeutics to treat inflammatory and neurodegenerative diseases. The AmideBio BioPure™ process provides the research community with some of the purest peptide-derived products available to date, including amyloid-beta, a protein that may be a key player in Alzheimer’s disease. The Company’s platform offers an economical and environmentally sustainable process for large-scale production, with the aim of providing patients with high quality, lower-cost medications